Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770908 | PMC |
| http://dx.doi.org/10.1053/j.gastro.2015.10.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ceftobiprole: A therapeutic update.
Am J Health Syst Pharm
January 2025
Pharmacotherapy Department, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, WA, USA.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFA Cross-Sectional Examination of Missed Infection Control Practices Among Nurses in the Jordanian Hospitals.
Workplace Health Saf
January 2025
Faculty of Nursing, The University of Jordan, Amman.
Background: Missed infection control practices may negatively impact quality healthcare and patient safety in acute health care settings. Hence, more research is urgently needed especially in Arab countries. To investigate the elements and reasons of missed infection control activities among nurses in Jordan.
View Article and Find Full Text PDFFever for days: A challenging case of dalbavancin-induced fever.
IDCases
December 2024
Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.
Dalbavancin is a novel long acting lipoglycopeptide antibiotic with a favorable safety profile approved for treating Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Gram-positive organisms. Given its long half-life, a two-dose regimen can provide effective systemic therapy for up to six weeks, making it an appealing option to avoid prolonged intravenous antibiotic therapy. Herein, we report a case of a 27-year-old male who developed dalbavancin-induced fever while treating Methicillin-sensitive (MSSA) bacteremia.
View Article and Find Full Text PDFClinical novel exploration of intractable fever in stroke rehabilitation: a single-center cross-sectional retrospective study.
Sci Rep
January 2025
Postgraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Fever has long been recognized as one of the earliest clinical indicators of illness and remains a leading reason for seeking medical care worldwide. It is typically classified based on its duration and underlying etiology. In clinical settings, intractable fever is as common as acute fever, particularly in patients with brain injuries.
View Article and Find Full Text PDFCOVID-19 infection and risk of adverse drug reactions: Cohort study.
Therapie
January 2025
Centre régional de pharmacovigilance, hôpital Nord, CHU de Saint-Étienne, 42055 Saint-Étienne cedex, France.
Aim: During coronavirus disease 2019 (COVID-19), the incidence rate of adverse drug reactions (ADRs) in hospitalized patients seemed higher than before the pandemic. Severe inflammation triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was cited as an explanation. We aimed to determine whether COVID-19 infection was associated with a higher risk of ADRs compared to other infectious diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!